We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.41%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$121M
Cap. Flow
-$26.6M
Cap. Flow %
-1.23%
Top 10 Hldgs %
45.97%
Holding
84
New
9
Increased
5
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$53.6M
2
LEGN icon
Legend Biotech
LEGN
+$39.2M
3
AKRO
Akero Therapeutics
AKRO
+$38.7M
4
IMGN
Immunogen Inc
IMGN
+$35M
5
ARGX icon
argenx
ARGX
+$29.5M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$204M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
3
BLU
BELLUS Health Inc.
BLU
+$23M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$7.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
1
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$146M 6.76%
1,430,004
+200,000
+16% +$18.9M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$144M 6.66%
1,576,000
– –
RVMD icon
3
Revolution Medicines
RVMD
$39.9B
$125M 5.81%
4,684,264
– –
TYRA icon
4
Tyra Biosciences
TYRA
$1.9B
$110M 5.09%
6,448,359
– –
SWTX
5
DELISTED
SpringWorks Therapeutics
SWTX
$89.7M 4.16%
3,421,541
– –
ONC
6
BeOne Medicines Ltd
ONC
$32.8B
$89.2M 4.13%
500,000
– –
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$78.3M 3.63%
1,676,733
+845,238
+102% +$38.7M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$72.3M 3.35%
2,000,000
– –
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.57B
$68.7M 3.19%
600,000
-175,000
-23% -$22.6M
CYTK icon
10
Cytokinetics
CYTK
$10.5B
$68.5M 3.18%
2,100,000
– –
IMGN
11
DELISTED
Immunogen Inc
IMGN
$55.9M 2.59%
+2,961,000
New +$35M
KRTX
12
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$54.2M 2.51%
+250,000
New +$53.6M
IDYA icon
13
IDEAYA Biosciences
IDYA
$3.42B
$51.8M 2.4%
2,202,812
– –
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$51.4M 2.39%
1,094,000
– –
NUVL
15
DELISTED
Nuvalent
NUVL
$51M 2.37%
1,210,192
– –
MRUS
16
DELISTED
Merus
MRUS
$50M 2.32%
1,900,000
– –
AMLX icon
17
Amylyx Pharmaceuticals
AMLX
$2.26B
$45M 2.08%
2,084,000
– –
LEGN icon
18
Legend Biotech
LEGN
$3.59B
$41.4M 1.92%
+600,000
New +$39.2M
ETNB
19
DELISTED
89bio
ETNB
$39.8M 1.85%
2,100,000
– –
RCUS icon
20
Arcus Biosciences
RCUS
$3.55B
$32.5M 1.51%
1,602,200
+170,000
+12% +$3.24M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$32.5M 1.51%
825,000
– –
VKTX icon
22
Viking Therapeutics
VKTX
$3.7B
$32.4M 1.5%
2,000,000
– –
ARGX icon
23
argenx
ARGX
$53.4B
$29.2M 1.36%
+75,000
New +$29.5M
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$29.2M 1.35%
2,325,000
– –
RCKT icon
25
Rocket Pharmaceuticals
RCKT
$340M
$29.1M 1.35%
1,466,051
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Boxer Capital held 84 positions worth $2.16B, up 5.9% from $2.04B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital's Q2 2023 filing shows 9 new, 5 increased, 5 reduced and 5 closed positions. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $204M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M.
  • Boxer Capital added most to Akero Therapeutics in Q2 2023, an estimated $38.7M increase.
  • Boxer Capital's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $22.6M.
  • Boxer Capital fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $204M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.16B portfolio in Q2 2023.
  • Boxer Capital opened 9 new positions and closed 5 in Q2 2023.
  • Boxer Capital's portfolio value rose 5.9% quarter-over-quarter to $2.16B.

Based on Boxer Capital's 13F filing for Q2 2023, filed 14 Aug 2023.